Industry strategies to reduce vector costs usually involve either ... in product approval delays due to raw material related regulatory challenges.” ...

The biopharmaceutical contract manufacturing market is expected to grow at a CAGR of 8.8% during the projected period. The ...

Higher costs in Vector’s regulated line network could be recovered through higher prices, although this was deferred by two years under the current regulatory model, he said. Mason said the ...